Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

248.97 +3.34 (+1.36%)

Streaming Delayed Price Updated: 1:23 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

25 26 Next >

Why Axsome Therapeutics Stock Is Soaring Today ↗

February 11, 2025

Via The Motley Fool

Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock ↗

February 10, 2025

Via Benzinga

Why Axsome Therapeutics Stock Is Skyrocketing Today ↗

February 10, 2025

Via The Motley Fool

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' ↗

February 10, 2025

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Via Benzinga

Topics Intellectual Property

Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday ↗

February 10, 2025

Via Benzinga

12 Analysts Have This To Say About Axsome Therapeutics ↗

January 21, 2025

Via Benzinga

Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts ↗

December 30, 2024

Via Benzinga

A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics ↗

November 12, 2024

Via Benzinga

Axsome Stock Rockets To Record High After Settling With Teva Over Depression Drug, Retail Optimism Swells ↗

February 10, 2025

Under the settlement terms, Teva will receive a license to sell a generic version of Auvelity starting March 31, 2039, if pediatric exclusivity is granted.

Via Stocktwits

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

February 10, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

January 31, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

January 30, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views ↗

October 04, 2024

Via Benzinga

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

January 22, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

January 13, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗

December 31, 2024

Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.

Via Benzinga

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation ↗

December 30, 2024

Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Via Investor's Business Daily

Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 30, 2024

Via Benzinga

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

December 30, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says ↗

November 27, 2024

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

Via Benzinga

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

November 26, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript ↗

November 12, 2024

AXSM earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

November 08, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

October 29, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Bargain Stocks to Buy in a Market That's Priced for Perfection ↗

October 19, 2024

Yes, bargains can still be found in the stock market.

Via The Motley Fool

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

October 15, 2024

From Axsome Therapeutics, Inc.

Via GlobeNewswire

1 Under-the-Radar Biotech Stock to Buy and Hold ↗

September 29, 2024

It could be an industry giant in the making.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.